Clinical Trial Update: Phase 2a, Exploratory Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of XPF-002 in Patients With Primary/Inherited Erythromelalgia [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2a exploratory study evaluating safety, efficacy, tolerability and pharmacokinetics of XPF-002 in patients with primary or inherited erythromelalgia; th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Erythromelalgia
• Inherited Erythromelalgia

Drugs mentioned

• XPF-002

Snippet

Sponsor: Xenon Pharmaceuticals Inc. | Conditions: Primary Erythromelalgia, Inherited Erythromelalgia | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2014-04-14